SIGYN THERAPEUTICS, INC.: 10-Q filed 2024-08-19
What SIGYN THERAPEUTICS, INC. reported in its quarterly report filed 2024-08-19 (fiscal Q2 2024): 34 published measures, 96 facts as tagged in accession 0001493152-24-033048.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2024-08-19
- Fiscal period
- fiscal Q2 2024
- Accession
- 0001493152-24-033048 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SIGYN THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 320,165 | USD | |
| At 2023-12-31 | 321,806 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 3,992,306 | USD | |
| At 2023-12-31 | 3,734,306 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | -3,672,141 | USD | |
| At 2024-03-31 | -4,021,254 | USD | |
| At 2023-12-31 | -3,412,500 | USD | |
| At 2023-06-30 | -3,042,217 | USD | |
| At 2023-03-31 | -2,346,037 | USD | |
| At 2022-12-31 | -1,903,239 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 53,644 | USD | |
| At 2023-12-31 | 11,690 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -862,383 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -1,620,471 | USD | 182 |
| 2024-01-01 to 2024-03-31 | -758,088 | USD | 91 |
| 2023-04-01 to 2023-06-30 | -723,124 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -2,064,160 | USD | 181 |
| 2023-01-01 to 2023-03-31 | -1,341,036 | USD | 90 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | -418,406 | USD | 182 |
| 2023-01-01 to 2023-06-30 | -891,267 | USD | 181 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 460,360 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 906,544 | USD | 181 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | -12,961,983 | USD | |
| At 2023-12-31 | -11,341,512 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 1,238,085 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 1,234,241 | shares | 182 |
| 2023-04-01 to 2023-06-30 | 1,083,277 | shares | 91 |
| 2023-01-01 to 2023-06-30 | 1,022,795 | shares | 181 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 1,238,085 | shares | 91 |
| 2024-01-01 to 2024-06-30 | 1,234,241 | shares | 182 |
| 2023-04-01 to 2023-06-30 | 1,083,277 | shares | 91 |
| 2023-01-01 to 2023-06-30 | 1,022,795 | shares | 181 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -0.7 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -1.31 | USD/shares | 182 |
| 2023-04-01 to 2023-06-30 | -0.67 | USD/shares | 91 |
| 2023-01-01 to 2023-06-30 | -2.02 | USD/shares | 181 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -0.7 | USD/shares | 91 |
| 2024-01-01 to 2024-06-30 | -1.31 | USD/shares | 182 |
| 2023-04-01 to 2023-06-30 | -0.67 | USD/shares | 91 |
| 2023-01-01 to 2023-06-30 | -2.02 | USD/shares | 181 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 12,411 | USD | |
| At 2023-12-31 | 15,296 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 75,000 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 75,000 | USD | 181 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -602,805 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -1,232,774 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -574,009 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -1,095,267 | USD | 181 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 146,376 | USD | |
| At 2023-12-31 | 118,063 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 3,899,617 | USD | |
| At 2023-12-31 | 3,608,004 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 488,364 | USD | |
| At 2023-12-31 | 461,646 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 602,805 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 1,232,774 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 574,009 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 1,095,267 | USD | 181 |
Net inventory
Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 50,000 | USD | |
| At 2023-12-31 | 50,000 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 240,429 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 473,022 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 219,159 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 367,002 | USD | 181 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 1,263,653 | shares | |
| At 2023-12-31 | 1,288,415 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 9,289,716 | USD | |
| At 2023-12-31 | 7,928,883 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 140,667 | USD | |
| At 2023-12-31 | 167,736 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 158,098 | USD |
Long-term debt
Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 2,010,027 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 19,787 | USD | |
| At 2023-12-31 | 16,902 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2024-06-30 | 20,711 | USD | |
| At 2023-12-31 | 20,711 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -862,383 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -1,620,471 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -723,124 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -2,064,160 | USD | 181 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 324,868 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 684,406 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 317,250 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 652,981 | USD | 181 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | 1,364 | USD | 91 |
| 2024-01-01 to 2024-06-30 | 2,885 | USD | 182 |
| 2023-04-01 to 2023-06-30 | 1,715 | USD | 91 |
| 2023-01-01 to 2023-06-30 | 3,430 | USD | 181 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-04-01 to 2024-06-30 | -259,578 | USD | 91 |
| 2024-01-01 to 2024-06-30 | -387,697 | USD | 182 |
| 2023-04-01 to 2023-06-30 | -149,115 | USD | 91 |
| 2023-01-01 to 2023-06-30 | -968,893 | USD | 181 |
Operating lease payments
Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 38,097 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 36,987 | USD | 181 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2024-01-01 to 2024-06-30 | 26,718 | USD | 182 |
| 2023-01-01 to 2023-06-30 | 12,427 | USD | 181 |
Inspect the source
- Entity
- SIGYN THERAPEUTICS, INC. / CIK 0001642159
- Captured
- 2026-09-21T17:22:56.950Z
- SEC response SHA-256
e0e4d7f4bb391730e2aba50a78fbec4c845e6f42106fcbd8cdabccf8b438da5e
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001642159.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))